Checking ovary health after immunotherapy for triple-negative breast cancer
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This study looks at how immunotherapy combined with chemotherapy affects ovary function in younger women with early-stage triple-negative breast cancer. It aims to understand if this treatment impacts fertility, which can help patients make informed decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 42 years old.
- You have early-stage triple-negative breast cancer (your doctor will confirm).
- You are scheduled to receive at least one dose of immunotherapy (such as pembrolizumab, atezolizumab, durvalumab, or nivolumab) along with chemotherapy before surgery.
- You are also scheduled to receive a GnRH agonist (a medicine that temporarily stops ovary function) with that chemotherapy.
- You have not had both ovaries removed or had radiation to the ovaries, and you have not had chemotherapy or immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.